Fig. 5
Distribution of PD-L1 positivity across the groups of tumors: A, mismatch repair-deficient—Lynch syndrome associated; B, mismatch-repair-deficient—unexplained; C, mismatch-repair-deficient—MLH1-methylated; D, mismatch-repair-proficient—tumor-infiltrating lymphocyte-high; E, mismatch-repair-proficient—consecutive. There is high expression in all mismatch-repair-deficient tumors and in mismatch-repair-proficient—tumor-infiltrating-lymphocyte-high tumors (p not significant), but distinctly low expression in mismatch-repair-proficient—consecutive tumors (p < 0.001)
